Clinical trial · Observational
Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. The main questions it aims to answer are: 1. What is the difference in urinary protein composition between patients with ovarian cancer and those without it? 2. Can these differences in urinary protein composition aid in the diagnosis of ovarian cancer? 3. Are urinary protein markers associated with tumor burden in urine samples from patients with ovarian cancer? 4. Can urinary protein markers be used for disease surveillance in ovarian cancer patients?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer (OvCa) | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Diagnosis undetermined
- description
- Patients who are initially diagnosed with conditions such as "pelvic mass" or "malignant ascites," which may suggest ovarian cancer, or those who are initially diagnosed with conditions such as "ovarian cyst," "hydrosalpinx," "uterine fibroids," or "adenomyosis," which are considered non-malignant gynecological diseases, and who have not yet undergone any surgery or treatment.
Primary outcomes (1)
- measure
- Pathological diagnosis
- timeFrame
- From enrollment to the end of surgery or biopsy at 1 weeks
- description
- The histological type of the disease is confirmed by surgery or biopsy
Secondary outcomes (1)
- measure
- Progression
- timeFrame
- From enrollment to the end of treatment at 6 months
- description
- Patients with ovarian cancer who have recurrent disease after initial treatment with serological or imaging evidence
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients in the gynecological ward for surgical treatment. * Initial diagnosis of "pelvic mass" or "malignant ascites" may be considered as ovarian cancer; Or the initial diagnosis of "ovarian cyst", "hydrosalpinx", "uterine fibroids" or "uterine adenomyosis" are considered as gynecological non-malignant diseases. * Over 18 years of age. * Voluntary participation and signing of informed consent. Exclusion Criteria: * Study participants with a prior history of malignant tumors. * Study participants with prior chronic kidney disease or renal insufficiency. * Study participants who have received or are receiving treatment for primary disease. * Study participants whose pathological diagnosis was not clear. Any patient should be excluded from the study if: * Study participants withdraw informed consent and request withdrawal. * Study participants were unable to provide a qualified urine sample. * There are situations in which the researcher considers it necessary to withdraw from the study.
References
Publications (0)
Data not yet available